Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia.

Simple item page
dc.contributor.authorDogra, Prem Nen_US
dc.contributor.authorBiswas, Nihar Ren_US
dc.contributor.authorRavi, Alok Ken_US
dc.contributor.authorMani, Kalaivanien_US
dc.contributor.authorKumar, Vinoden_US
dc.date.accessioned2005-02-13en_US
dc.date.accessioned2009-05-31T17:02:06Z
dc.date.available2005-02-13en_US
dc.date.available2009-05-31T17:02:06Z
dc.date.issued2005-02-13en_US
dc.description.abstractThe objective of the present study was to evaluate the efficacy and safety of Prostina, a multi-ingredient herbal formulation in benign prostatic hyperplasia (BPH) in comparison with terazosin. A randomised, open, parallel, controlled clinical trial was carried out in ambulatory men aged between 40-80 years suffering from BPH, with American Urological Association (AUA) symptom index score of at least 8 or more at recruitment. One group received 2 Prostina capsules twice daily for 12 weeks; the other received terazosin 2 mg at bedtime for 12 weeks. Urodynamic parameters, AUA score, biochemical and clinical adverse effects were assessed. Twenty subjects completed the study in Prostina group and 20 in terazosin group. The groups were comparable at baseline in age and assessment criteria. Majority of urodynamic parameters showed improving trends in both the groups. AUA symptom score declined significantly from 19.50 +/- 1.40 (mean +/- standard error) to 1.04 +/- 0.68 in Prostina group and from 16.95 +/- 1.23 to 4.14 +/- 0.88 in terazosin group. The AUA symptom score in 12 weeks follow-up was significantly lower in Prostina group than terazosin group (p = 0.005). Other laboratory-parameters remained unaltered in both the groups. Prostina is as effective as terazosin in providing symptomatic relief in BPH.en_US
dc.description.affiliationDepartment of Urology, AIIMS, New Delhi 110029.en_US
dc.identifier.citationDogra PN, Biswas NR, Ravi AK, Mani K, Kumar V. Comparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia. Journal of the Indian Medical Association. 2005 Feb; 103(2): 108-10, 112en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/104786
dc.language.isoengen_US
dc.source.urihttps://www.jimaonline.org.in/en_US
dc.subject.meshAdrenergic alpha-Antagonists --therapeutic useen_US
dc.subject.meshAgeden_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPhytotherapyen_US
dc.subject.meshPlants, Medicinalen_US
dc.subject.meshPrazosin --analogs & derivativesen_US
dc.subject.meshProstatic Hyperplasia --drug therapyen_US
dc.subject.meshUrodynamics --drug effectsen_US
dc.titleComparative evaluation of Prostina and terazosin in the treatment of benign prostatic hyperplasia.en_US
dc.typeClinical Trialen_US
dc.typeComparative Studyen_US
dc.typeJournal Articleen_US
dc.typeRandomized Controlled Trialen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Journal of the Indian Medical Association